Comparison · NCT04410328-c4a6bc35
Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: Mortality
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Participants Receiving Dipyridamole and Aspirin vs Participants Receiving Standard of Care: Mortality. Trial comparisons, record NCT04410328-c4a6bc35. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04410328-c4a6bc35
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0612 | 0.021 | 0.165 | wilson | |
| Risk in group 2 | 0.102 | 0.0444 | 0.218 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0408 | -0.163 | 0.0781 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.6 | 0.152 | 2.37 | log | |
| Odds ratio, group 1 over group 2 | 0.574 | 0.129 | 2.55 | log | |
| Number needed to treat, for one fewer participant with the outcome on Participants Receiving Dipyridamole and Aspirin than on Participants Receiving Standard of Care | 24.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: standard of care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Participants Receiving Dipyridamole and Aspirin | Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally plus standard care. Participants will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally), 2 times daily starting on the day of enrollment for a total of 2 weeks.~Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care: Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.~Standard of care: Participants will receive standard care starting on the day of enrollment for a total of 2 weeks. | 3 | 49 | OG000 |
| Group 2 | Participants Receiving Standard of Care | Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.~Standard of care: Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.~Standard of care treatment consist of an intravenous Remidesivir 200 mg loading dose and then 100 mg/daily for a total of 4 days for non-intubated patients and 10 days for intubated patients, intravenous/oral decadron 6 mg/daily for 10 days and prophylactic subcutaneous LMWH daily, started on the day of enrollment and for the duration of hospitalization. If the patients are discharged before 10 days, they are prescribed oral decadron 6 mg daily to complete the course of 10 days | 5 | 49 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Mortality
- Description
- All-cause mortality assessed on day 28.
- Time frame
- 28 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Aggrenox To Treat Acute Covid-19
- NCT number
- NCT04410328
- Phases
- PHASE3
- Conditions
- Covid19
- Interventions
- Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care
- Lead sponsor
- Rutgers, The State University of New Jersey
- Results first posted
- 2025-02-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04410328?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04410328-c4a6bc35